Published in Bioorg Med Chem on April 19, 2013
The emerging role of Nrf2 in mitochondrial function. Free Radic Biol Med (2015) 1.15
Small molecules, big targets: drug discovery faces the protein-protein interaction challenge. Nat Rev Drug Discov (2016) 0.93
The emerging role of native mass spectrometry in characterizing the structure and dynamics of macromolecular complexes. Protein Sci (2015) 0.89
Structural basis of Keap1 interactions with Nrf2. Free Radic Biol Med (2015) 0.88
Discovery of direct inhibitors of Keap1-Nrf2 protein-protein interaction as potential therapeutic and preventive agents. Acta Pharm Sin B (2015) 0.86
Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway. Int J Mol Sci (2015) 0.86
Targeting Cullin-RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation. Biochem J (2015) 0.85
p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming. Nat Commun (2016) 0.84
New strategies to inhibit KEAP1 and the Cul3-based E3 ubiquitin ligases. Biochem Soc Trans (2014) 0.82
Dimethyl Fumarate Inhibits the Nuclear Factor κB Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein. J Biol Chem (2015) 0.80
Probing the structural requirements of non-electrophilic naphthalene-based Nrf2 activators. Eur J Med Chem (2015) 0.78
Characterization of RA839, a Noncovalent Small Molecule Binder to Keap1 and Selective Activator of Nrf2 Signaling. J Biol Chem (2015) 0.78
Non-electrophilic modulators of the canonical Keap1/Nrf2 pathway. Bioorg Med Chem Lett (2015) 0.78
Development of a steady-state FRET-based assay to identify inhibitors of the Keap1-Nrf2 protein-protein interaction. Protein Sci (2013) 0.78
Focused grid-based resampling for protein docking and mapping. J Comput Chem (2016) 0.77
Multiple binding modes of a small molecule to human Keap1 revealed by X-ray crystallography and molecular dynamics simulation. FEBS Open Bio (2015) 0.76
Nrf2 inhibits epithelial-mesenchymal transition by suppressing snail expression during pulmonary fibrosis. Sci Rep (2016) 0.75
Polar Recognition Group Study of Keap1-Nrf2 Protein-Protein Interaction Inhibitors. ACS Med Chem Lett (2016) 0.75
An Intriguing Correlation Based on the Superimposition of Residue Pairs with Inhibitors that Target Protein-Protein Interfaces. Sci Rep (2016) 0.75
Esculetin induces antiproliferative and apoptotic response in pancreatic cancer cells by directly binding to KEAP1. Mol Cancer (2016) 0.75
Optimization of Electrospray Ionization by Statistical Design of Experiments and Response Surface Methodology: Protein-Ligand Equilibrium Dissociation Constant Determinations. J Am Soc Mass Spectrom (2016) 0.75
NAD(P)H:quinone oxidoreductase 1 inducer activity of some novel anilinoquinazoline derivatives. Drug Des Devel Ther (2016) 0.75
The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev (2016) 0.75
The status of Nrf2-based therapeutics: current perspectives and future prospects. Neural Regen Res (2016) 0.75
Metabolic and Homeostatic Changes in Seizures and Acquired Epilepsy-Mitochondria, Calcium Dynamics and Reactive Oxygen Species. Int J Mol Sci (2017) 0.75
Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol (2008) 9.24
Emergence of fatal PRRSV variants: unparalleled outbreaks of atypical PRRS in China and molecular dissection of the unique hallmark. PLoS One (2007) 5.60
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain (2011) 3.38
TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol (2010) 3.26
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol (2011) 3.21
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol (2012) 3.00
LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci (2005) 2.61
miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood (2008) 2.58
Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther (2012) 2.22
Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol (2006) 2.15
Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models. Cell Stem Cell (2011) 2.04
Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother (2009) 2.02
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol (2009) 2.00
Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica (2007) 1.99
Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity. J Infect Dis (2011) 1.96
Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J Med Chem (2008) 1.96
Gene expression profiling of cutaneous wound healing. J Transl Med (2007) 1.91
MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells. J Transl Med (2009) 1.85
Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme. Chem Biol (2012) 1.82
Global transcriptome analysis of human bone marrow stromal cells (BMSC) reveals proliferative, mobile and interactive cells that produce abundant extracellular matrix proteins, some of which may affect BMSC potency. Cytotherapy (2011) 1.73
Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains. Proc Natl Acad Sci U S A (2010) 1.61
High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood (2012) 1.58
Common cancer biomarkers. Cancer Res (2006) 1.56
Affinity enhancement of an in vivo matured therapeutic antibody using structure-based computational design. Protein Sci (2006) 1.55
Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases. Protein Sci (2010) 1.53
Religious attendance as a predictor of survival in the EPESE cohorts. Int J Epidemiol (2005) 1.52
Systems-based design of bi-ligand inhibitors of oxidoreductases: filling the chemical proteomic toolbox. Chem Biol (2004) 1.52
Amphioxus postembryonic development reveals the homology of chordate metamorphosis. Curr Biol (2008) 1.51
An unusual feature of end-substituted model carbon (6,0) nanotubes. J Mol Model (2005) 1.47
Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML). PLoS Genet (2009) 1.43
Structure of a NEMO/IKK-associating domain reveals architecture of the interaction site. Structure (2008) 1.39
Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. MAbs (2009) 1.30
BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther (2009) 1.29
Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Biol Chem (2002) 1.29
Activation of RXR-PPAR heterodimers by organotin environmental endocrine disruptors. EMBO Rep (2009) 1.29
Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng Des Sel (2010) 1.27
Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A (2010) 1.24
Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serotype A. Antimicrob Agents Chemother (2009) 1.21
Rational optimization of reprogramming culture conditions for the generation of induced pluripotent stem cells with ultra-high efficiency and fast kinetics. Cell Res (2011) 1.19
Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes. Blood (2005) 1.16
Dual role for TWEAK in angiogenic regulation. J Cell Sci (2002) 1.16
Intraoperative MRI to guide the resection of primary supratentorial glioblastoma multiforme--a quantitative radiological analysis. Neuroradiology (2005) 1.15
Crystal structure of Thermus thermophilus tRNA m1A58 methyltransferase and biophysical characterization of its interaction with tRNA. J Mol Biol (2008) 1.09
NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood (2013) 1.09
A hybrid recursion method to robustly ensure convergence efficiencies in the simulated scaling based free energy simulations. J Chem Phys (2008) 1.08
OsCOL4 is a constitutive flowering repressor upstream of Ehd1 and downstream of OsphyB. Plant J (2010) 1.06
Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist. J Pharmacol Exp Ther (2007) 1.05
Intra-subject variability in human bone marrow stromal cell (BMSC) replicative senescence: molecular changes associated with BMSC senescence. Stem Cell Res (2013) 1.05
Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody. J Pharmacol Exp Ther (2013) 1.04
A methylation-dependent electrostatic switch controls DNA repair and transcriptional activation by E. coli ada. Mol Cell (2005) 1.03
Preparation of hollow hydroxyapatite microspheres. J Mater Sci Mater Med (2006) 1.03
TRAF3 controls activation of the canonical and alternative NFkappaB by the lymphotoxin beta receptor. J Biol Chem (2010) 1.03
Effects of strontium in modified biomaterials. Acta Biomater (2010) 1.03
Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis. Protein Sci (2010) 1.02
Design of next-generation protein therapeutics. Curr Opin Chem Biol (2010) 1.02
Evaluation of 3 clinical dendritic cell maturation protocols containing lipopolysaccharide and interferon-gamma. J Immunother (2009) 1.01
Neutralization of Clostridium difficile toxin A using antibody combinations. MAbs (2011) 1.01
Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy. Cancer Res (2006) 1.01
Artemin crystal structure reveals insights into heparan sulfate binding. Biochemistry (2006) 1.01
Control of transposon activity by a histone H3K4 demethylase in rice. Proc Natl Acad Sci U S A (2013) 1.00
Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and -133a. J Transl Med (2009) 1.00
Active-specific immunization against melanoma: is the problem at the receiving end? Semin Cancer Biol (2003) 1.00
Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment. Biomaterials (2013) 1.00
Monocyte-derived DC maturation strategies and related pathways: a transcriptional view. Cancer Immunol Immunother (2011) 0.99
Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist. J Med Chem (2006) 0.99
Inactivation of the CTD phosphatase-like gene OsCPL1 enhances the development of the abscission layer and seed shattering in rice. Plant J (2009) 0.99
Formation of virus-like clusters is an intrinsic property of the tumor necrosis factor family member BAFF (B cell activating factor). Biochemistry (2006) 0.99
Identification of potent and selective amidobipyridyl inhibitors of protein kinase D. J Med Chem (2010) 0.98
Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. J Biol Chem (2010) 0.97
Structure activity relationships of monocyte chemoattractant proteins in complex with a blocking antibody. Protein Eng Des Sel (2006) 0.96
Comparison of two capillary gel electrophoresis systems for Clostridium difficile ribotyping, using a panel of ribotype 027 isolates and whole-genome sequences as a reference standard. J Clin Microbiol (2012) 0.95
Structural understanding of stabilization patterns in engineered bispecific Ig-like antibody molecules. Proteins (2009) 0.94
A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. Cancer Res (2009) 0.94
Pancreatic islet cell therapy for type I diabetes: understanding the effects of glucose stimulation on islets in order to produce better islets for transplantation. J Transl Med (2007) 0.94
Identification of orally available naphthyridine protein kinase D inhibitors. J Med Chem (2010) 0.94
Bioactive borosilicate glass scaffolds: improvement on the strength of glass-based scaffolds for tissue engineering. J Mater Sci Mater Med (2008) 0.93
Rapid analysis of Forster resonance energy transfer by two-color global fluorescence correlation spectroscopy: trypsin proteinase reaction. Biophys J (2005) 0.93
Comparison of endometrial regenerative cells and bone marrow stromal cells. J Transl Med (2012) 0.92
Teicoplanin-loaded borate bioactive glass implants for treating chronic bone infection in a rabbit tibia osteomyelitis model. Biomaterials (2010) 0.92
Processing of anti-mullerian hormone regulates receptor activation by a mechanism distinct from TGF-beta. Mol Endocrinol (2010) 0.92
Leukemia cells induce changes in human bone marrow stromal cells. J Transl Med (2013) 0.92
Development of a 24-locus multiplex system to incorporate the core loci in the Combined DNA Index System (CODIS) and the European Standard Set (ESS). Forensic Sci Int Genet (2013) 0.91
Development of a 20-locus fluorescent multiplex system as a valuable tool for national DNA database. Forensic Sci Int Genet (2012) 0.91
Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery. Bioorg Med Chem Lett (2011) 0.91
Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia. Haematologica (2009) 0.91
New approaches for the treatment of pain: the GDNF family of neurotrophic growth factors. Curr Top Med Chem (2005) 0.91
Characterization of inhibitory anti-insulin-like growth factor receptor antibodies with different epitope specificity and ligand-blocking properties: implications for mechanism of action in vivo. J Biol Chem (2009) 0.91